Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.53
-0.8400-2.03%
Post-market: 40.810.2800+0.69%18:03 EDT
Volume:3.99M
Turnover:162.05M
Market Cap:2.89B
PE:-8.69
High:42.21
Open:40.95
Low:40.14
Close:41.37
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:3.91
T/O Rate:7.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.78
PE(LYR):-8.69

Loading ...

Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)

TIPRANKS
·
Mar 17

Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears

Simply Wall St.
·
Mar 16

Vera Therapeutics Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
Mar 11

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Mar 11

Vera Therapeutics appoints Christopher Hite to board

Reuters
·
Mar 10

Vera Therapeutics Grants Inducement Stock Options and RSUs to Six New Hires

Reuters
·
Mar 07

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Vera Therapeutics appoints Hite to Board of Directors

TIPRANKS
·
Mar 05

Vera Therapeutics Appoints Christopher Hite to Board of Directors

GlobeNewswire
·
Mar 05

Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Mar 02

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

TIPRANKS
·
Mar 02

Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)

Simply Wall St.
·
Feb 28

Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating

TIPRANKS
·
Feb 28

Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating

MT Newswires Live
·
Feb 27

Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Feb 27

Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate

Benzinga
·
Feb 27

Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity

TIPRANKS
·
Feb 27

Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Vera Therapeutics' 2025 net loss wider than expectations

Reuters
·
Feb 26